Results 211 to 220 of about 192,309 (409)
Sparse two-stage Bayesian meta-analysis for individualized treatments [PDF]
arXivIndividualized treatment rules tailor treatments to patients based on clinical, demographic, and other characteristics. Estimation of individualized treatment rules requires the identification of individuals who benefit most from the particular treatments and thus the detection of variability in treatment effects. To develop an effective individualized
arxiv
High coumarin 7-hydroxylase activity does not protect mice against Warfarin [PDF]
, 1975 Ian E. Lush, Colette Arnold
openalex +1 more source
Opportunities and Challenges of Population Pharmacogenomics
Annals of Human Genetics, EarlyView.ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou +3 more
wiley +1 more source
Frontiers in PharmacologyWarfarin is an anticoagulant that requires INR-based dosage adjustment. Ascorbic acid may impair warfarin effectiveness according to limited literature.
Pingfa Gao +4 more
doaj +1 more source
May mothers given warfarin breast-feed their infants? [PDF]
, 1977 Michael Orme +6 more
openalex +1 more source
ANZ Journal of Surgery, EarlyView.With the increasing use of NOAC and the availability of reversal agents, there remains sparse evidence regarding its use in POAF. The use of a NOAC in patients with POAF did not appear to increase short‐term postoperative complications, including bleeding, stroke, readmission rates and mortality, compared with warfarin.
Shantel Chang +5 more
wiley +1 more source
Comparison of a new microcrystalline dicoumarol preparation with warfarin under routine treatment conditions. [PDF]
, 1979 D. Lockner, Claudia Paul
openalex +1 more source